albumin - publications

Predict more albumin - ligand interactions now!

1. Regul Pept. 2012 Jan 29. [Epub ahead of print]

Characterization of a long-acting recombinant human serum albumin-atrial
natriuretic factor (ANF) expressed in Pichia pastoris.

de Bold MK, Sheffield WP, Martinuk A, Bhakta V, Eltringham-Smith L, de Bold AJ.

University of Ottawa Heart Institute, Ottawa, ON, Canada K1Y 4E7.

The cardiac hormone atrial natriuretic factor (ANF) combines pharmacological
properties of drugs used to treat essential hypertension (EH), congestive heart
failure (CHF) and acute myocardial infarction (AMI). Treatment of CHF or AMI
patients with an intravenous (iv) infusion of the circulating form of ANF
(ANF(99-126)) produces significant clinical improvement. The short half-life
(5min) and peptide nature of ANF impose logistic restrictions for chronic
administration. To increase its half-life, we fused ANF and human serum albumin
(HSA) mini-genes by recombination in Pichia pastoris. The activity of three
configurations of the fusion protein was tested in vitro and in vivo. The fusion
protein that comprised of C-terminus HSA connected to N-terminus ANF via a
hexaglycine linker showed the best outcome; it increased cGMP production in
vitro. In vivo an iv bolus of HSA-ANF into mice increased significantly plasma
cGMP levels and lowered blood pressure (BP) for up to 6h hence successfully
extended ANF half-life in plasma while retaining its biological activity. HSA-ANF
represents the basis for development in the chronic therapeutic use of ANF.

Copyright © 2012 Elsevier B.V. All rights reserved.

PMID: 22296859 [PubMed - as supplied by publisher]